Reetoo Biotech

What Reetoo Biotech does

Reetoo Biotech (深圳市瑞图生物技术有限公司) is a Shenzhen-based, privately held biotechnology company founded in 2017 that develops AI-powered in vitro diagnostic (IVD) instruments and reagents for hospital clinical laboratories in China and select international markets. The company's core offering is built around its proprietary DeepCell engine — a deep-learning image recognition system for cell morphology analysis — applied across eight specimen types (blood, vaginal discharge, semen, chromosomes, urine, feces, sputum, and tissue). Reetoo claims to be the only company globally providing full-specimen, full-process, fully automated, and fully intelligent testing products in this category, with flagship systems including the RT-F600 and RT-F2000A vaginal secretion detectors (60–90 tests/hour throughput), the RT-i1000 chromosome karyotyping system, the RT-S100 semen quality analyzer, the D3500/D3100 automated stainers, the MS2100 micro-image scanner, and a full-channel automated blood analysis pipeline launched in 2024.

The company monetizes through a classic IVD razor-and-blade model: one-time equipment sales paired with recurring reagent and consumable revenue, supported by 11 Class II NMPA reagent registrations and 84 CE certifications. Go-to-market is enterprise field sales targeting top-tier Grade A academic medical centers as reference customers — including Wuhan Union Hospital, Nanjing Drum Tower Hospital, and Sichuan Provincial People's Hospital — then radiating outward to smaller hospitals. Distribution combines 32 provincial direct service centers across mainland China with a growing international distributor footprint in Europe and the Middle East built around major industry exhibitions (CACLP, AACC, MEDICA, ARABHEALTH).

Reetoo has scaled from approximately 20 employees at founding to 300+ headcount (around 40% in R&D), with a 14,000 square meter R&D and production base, cumulative R&D investment exceeding 300 million RMB, and more than 400 patents / 500+ intellectual property rights. The company has raised a Series 2 round of approximately USD 14M from CAS Investment Management and Shenzhen Investment Holdings in December 2023, and has been recognized as a National High-Tech Enterprise, a 2022 Scientist Entrepreneur Pioneer firm, and a Greater Bay Area Bio-tech Innovation Top 50 Pioneer Enterprise. Its competitive position rests on regulatory breadth, a self-improving AI model trained against data from 500+ hospital installations, and leadership of the national expert consensus initiative for vaginal secretion testing in partnership with 30+ Grade A hospitals.

Name

Reetoo Biotech

Legal name

深圳市瑞图生物技术有限公司

Website

https://reetoo.com.cn

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Reetoo Biotech is a Shenzhen-based AI-powered in vitro diagnostics (IVD) company that develops automated cell morphology recognition analyzers and reagents for hospital clinical laboratories, serving over 500 Grade A and B hospitals across China and select international markets with its proprietary DeepCell engine.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD) Medical Devices

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

Keywords

• AI medical diagnostics
• In vitro diagnostics
• Clinical laboratory automation
• Cell morphology analysis
• Cytology imaging systems

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. IVD Equipment Sales: Sale of automated medical diagnostic instruments including vaginal secretion detectors (RT-F600, RT-F2000A), automatic chromosome imaging systems (RT-i1000), sperm quality analyzers (RT-S100), and blood analysis assembly lines.
2. IVD Reagents: Sale of diagnostic reagents and consumables for use with the company's diagnostic platforms. The company holds 11 Class II NMPA registrations and 24 medical device product filings.
3. Intelligent Laboratory Solutions: Complete laboratory automation solutions integrating multiple testing workstations into intelligent laboratory configurations including intelligent blood collection, central control, genetic testing, molecular diagnostics, microbiology, pathology, hematology, and body fluid laboratories.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Reetoo Biotech develops and manufactures AI-powered In Vitro Diagnostics (IVD) instruments for clinical laboratories. The company produces automated analyzers for cell morphology-based testing, including vaginal secretion detectors, chromosome karyotyping systems, sperm quality analyzers, blood analysis pipelines, and automated staining machines, all driven by a proprietary DeepCell AI engine for image recognition and cell classification.

Product overview

Reetoo Biotech offers a comprehensive AI-powered IVD (In Vitro Diagnostics) platform covering clinical testing, reproductive genetics, and microbiology laboratories. The product portfolio includes the flagship RT-F600 and RT-F2000A vaginal secretion detection analyzers (60-90 tests/hour), RT-i1000 automated chromosome micro-imaging scanning system, RT-S100 semen quality analyzer, D3500/D3100 automated staining machines, MS2100 micro-image scanner, and the full-channel automated blood analysis pipeline. The company provides full-specimen, full-process, full-automation, and full-intelligence testing products. Core technology is powered by the proprietary DeepCell AI engine enabling high-accuracy cell recognition (>90%) with self-learning capabilities. The solutions integrate specimen processing, digital imaging, and AI-based classification for medical diagnostics.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Testing efficiency increased by 10x compared to manual methods
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

One partnership is on record.

• 30+ Grade A Hospitals (三甲医院)coreStrategic or Co-development Partner · 1 January 2021Reetoo Biotech leads a consortium of over 30 Grade A hospitals as the lead unit to draft the national expert consensus for vaginal secretion specimen testing. This collaboration establishes industry standards and clinical validation for the company's AI diagnostic products.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mindray (Shenzhen Mindray Bio-Medical Electronics): China's largest IVD and medical device company, offering competing automated hematology, clinical chemistry, and cell morphology analyzers. Both companies target Chinese tertiary hospitals with reagent-attached instrument platforms; Mindray is the dominant incumbent Reetoo must displace.
• Sysmex Corporation: Global leader in hematology and cell morphology IVD, with strong AI-enabled blood cell analysis (DI-60 digital morphology). Reetoo's vaginal secretion, chromosome, and blood analysis products compete directly with Sysmex's installed base in clinical laboratories.
• Hologic: Specialist in women's health diagnostics, including ThinPrep cytology and AI-enabled cervical cancer screening (Genius). Reetoo's vaginal secretion and cervical cancer AI workstation directly compete with Hologic's cytology franchise in OB/GYN and hospital labs.
• Autobio Diagnostics: Major Chinese IVD company with strong clinical microbiology, immunology, and chemiluminescence platforms. Competes with Reetoo in the Chinese hospital microbiology and clinical chemistry segments with comparable reagent-attached instrument economics.
• Snibe (Shenzhen New Industries Biomedical Engineering): Leading Chinese IVD company specializing in chemiluminescence immunoassays and clinical chemistry analyzers. Directly comparable as a Shenzhen-headquartered Chinese IVD player targeting the same hospital channel with automated instruments and reagent kits.

Broad incumbents

• Beckman Coulter (Danaher): Major global IVD player with broad hematology, clinical chemistry, and cellular analysis portfolios including AI-driven cell imaging. Competes with Reetoo in the same hospital lab segment but serves a much wider IVD menu globally.
• Roche Diagnostics: World's largest IVD company with comprehensive cell morphology, molecular, and clinical chemistry solutions. Represents the dominant global incumbent whose AI morphology roadmap Reetoo's DeepCell engine attempts to disrupt.
• Siemens Healthineers: Global IVD and imaging powerhouse with AI-augmented Atellica and ADVIA Centaur systems covering hematology, clinical chemistry, and immunoassays. Overlaps with Reetoo's clinical laboratory automation ambitions but at a much broader portfolio scale.
• Abbott Diagnostics: Major global IVD provider with Alinity ci-series hematology and clinical chemistry systems. Competes broadly with Reetoo's laboratory automation and clinical testing solutions in international and high-end Chinese hospital segments.

Emerging players

• DiagCor Bioscience: Hong Kong-based molecular diagnostics and genetic testing company with overlapping women's health and reproductive genetics offerings. Competes in the chromosome karyotyping and reproductive genetics segments where Reetoo's RT-i1000 is positioned.

Market position

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reetoo Biotech